pbs tirzepatide FDA Grants a New Indication for Obesity Management Compounding pharmacies can resume making

A gradual climb from the starting dose to the maximum therapeutic dose

Extended heat exposure can cause: Color darkening or brownish shifts Cloudiness from peptide aggregation Visible particle formation Loss of potency even without visible changes If your medication was shipped without adequate cold chain protection, or if it sat in a hot mailbox or delivery vehicle for hours, inspect it carefully before use

It is usually mild and temporary, and may be related to metabolic changes, weight loss, or the body adjusting to treatment rather than a direct effect of the medication

The deadline for 503A pharmacies was February 18, 2025, and for 503B outsourcing facilities was March 19, 2025

Some formulations with preservatives like benzyl alcohol may last longer

Its BBB standing is imperfect, with active complaints and a "Not Rated" status, but that is a meaningfully different picture than an F rating paired with a named FDA warning letter